PMID- 22968678
OWN - NLM
STAT- MEDLINE
DCOM- 20130228
LR  - 20211021
IS  - 1573-7241 (Electronic)
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 26
IP  - 5
DP  - 2012 Oct
TI  - Metformin in non-diabetic patients presenting with ST elevation myocardial 
      infarction: rationale and design of the glycometabolic intervention as adjunct to 
      primary percutaneous intervention in ST elevation myocardial infarction 
      (GIPS)-III trial.
PG  - 417-26
LID - 10.1007/s10557-012-6413-1 [doi]
AB  - BACKGROUND: Left ventricular dysfunction and the development of heart failure is 
      a frequent and serious complication of myocardial infarction. Recent animal 
      experimental studies suggested that metformin treatment reduces myocardial injury 
      and preserves cardiac function in non-diabetic rats after experimental myocardial 
      infarction. We will study the efficacy of metformin with the aim to preserve left 
      ventricular ejection fraction in non-diabetic patients presenting with ST 
      elevation myocardial infarction (STEMI). METHODS: The Glycometabolic Intervention 
      as adjunct to Primary percutaneous intervention in ST elevation myocardial 
      infarction (GIPS)-III trial is a prospective, single center, double blind, 
      randomized, placebo-controlled trial. Three-hundred-and-fifty patients, without 
      diabetes, requiring primary percutaneous coronary intervention (PCI) for STEMI 
      will be randomized to metformin 500 mg twice daily or placebo treatment and will 
      undergo magnetic resonance imaging (MRI) after 4 months. Major exclusion criteria 
      were prior myocardial infarction and severe renal dysfunction. The primary 
      efficacy parameter is left ventricular ejection fraction 4 months after 
      randomization. Secondary and tertiary efficacy parameters include major adverse 
      cardiac events, new onset diabetes and glycometabolic parameters, and 
      echocardiographic diastolic function. Safety parameters include renal function 
      deterioration and lactic acidosis. CONCLUSIONS: The GIPS-III trial will evaluate 
      the efficacy of metformin treatment to preserve left ventricular ejection 
      fraction in STEMI patients without diabetes.
FAU - Lexis, Chris P H
AU  - Lexis CP
AD  - Department of Cardiology, University Medical Center Groningen, University of 
      Groningen, Hanzeplein 1, 9700 RB, PO Box 30.001, Groningen, the Netherlands. 
      c.p.h.lexis@umcg.nl
FAU - van der Horst, Iwan C C
AU  - van der Horst IC
FAU - Lipsic, Erik
AU  - Lipsic E
FAU - van der Harst, Pim
AU  - van der Harst P
FAU - van der Horst-Schrivers, Anouk N A
AU  - van der Horst-Schrivers AN
FAU - Wolffenbuttel, Bruce H R
AU  - Wolffenbuttel BH
FAU - de Boer, Rudolf A
AU  - de Boer RA
FAU - van Rossum, Albert C
AU  - van Rossum AC
FAU - van Veldhuisen, Dirk J
AU  - van Veldhuisen DJ
FAU - de Smet, Bart J G L
AU  - de Smet BJ
CN  - GIPS-III Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01217307
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Metformin/*therapeutic use
MH  - Myocardial Infarction/*drug therapy/surgery
MH  - Percutaneous Coronary Intervention
MH  - Ventricular Dysfunction, Left/*drug therapy/surgery
MH  - Ventricular Function, Left/drug effects/physiology
PMC - PMC3464381
FIR - Lexis, C P H
IR  - Lexis CP
FIR - van der Horst, I C C
IR  - van der Horst IC
FIR - Wieringa, W G
IR  - Wieringa WG
FIR - Lipsic, E
IR  - Lipsic E
FIR - van der Harst, P
IR  - van der Harst P
FIR - van Veldhuisen, D J
IR  - van Veldhuisen DJ
FIR - de Smet, B J G L
IR  - de Smet BJ
FIR - van der Werf, H W
IR  - van der Werf HW
FIR - Schurer, R A J
IR  - Schurer RA
FIR - Pundziute, G P
IR  - Pundziute GP
FIR - van den Heuvel, A F M
IR  - van den Heuvel AF
FIR - Tan, E S
IR  - Tan ES
FIR - Gerds, H Z R
IR  - Gerds HZ
FIR - de Boer, R A
IR  - de Boer RA
FIR - Willemsen, M H
IR  - Willemsen MH
FIR - Nieuwland, W
IR  - Nieuwland W
FIR - Coster, J
IR  - Coster J
FIR - Tio, R A
IR  - Tio RA
FIR - van der Meer, P
IR  - van der Meer P
FIR - Dorhout, B
IR  - Dorhout B
FIR - ter Horst, G J
IR  - ter Horst GJ
FIR - van der Horst-Schrivers, A N A
IR  - van der Horst-Schrivers AN
EDAT- 2012/09/13 06:00
MHDA- 2013/03/01 06:00
PMCR- 2012/09/12
CRDT- 2012/09/13 06:00
PHST- 2012/09/13 06:00 [entrez]
PHST- 2012/09/13 06:00 [pubmed]
PHST- 2013/03/01 06:00 [medline]
PHST- 2012/09/12 00:00 [pmc-release]
AID - 6413 [pii]
AID - 10.1007/s10557-012-6413-1 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 2012 Oct;26(5):417-26. doi: 10.1007/s10557-012-6413-1.